INNOTEST^® NPTX2

This assay should be used in combination with the NPTX2 CAL-RVC pack, article no. 80909 (RUO), of the corresponding lot.
 

Test principle

The INNOTEST NPTX2 is a solid-phase enzyme immunoassay in which the neuronal pentraxin-2 protein is captured by a first monoclonal antibody, 33F9 (ADx409; IgG1). CSF samples are added and incubated with a biotinylated antibody, 22H10 (ADx410; IgG2a). This antigen-antibody complex is then detected by a peroxidase-labeled streptavidin. After addition of substrate working solution, samples will develop a color. The color intensity is a measure for the amount of human neuronal pentraxin-2 protein in the sample^1,2.

Test principle INNOTEST NPTX2 (SV= streptavidin; HRP= horseradish peroxidase).

 
Background

Neuronal pentraxin-2 is a synaptic protein that consistently shows decreased CSF concentrations in Alzheimer’s disease compared to control subjects^1,2. Preliminary studies indicate that while CSF NPTX2 correlates poorly with the core CSF biomarkers (β-amyloid and tau) and other synaptic markers, it seems to correlate well with cognitive decline².

 
References

1. Jacobs D, et al. A monoclonal antibody based immunoassay for Neuronal Pentraxin2 in CSF. ADPD 2019.
2. Vanmechelen E, et al. NPTX2 levels in CSF as potential predictor of cognitive dysfunction in the AD continuum. AAIC 2019.